The lancet oncology
-
The lancet oncology · Mar 2021
Randomized Controlled Trial Multicenter Study Comparative StudyEndoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial.
The role of surgery compared with reirradiation in the primary treatment of patients with resectable, locally recurrent nasopharyngeal carcinoma (NPC) who have previously received radiotherapy is a matter of debate. In this trial, we compared the efficacy and safety outcomes of salvage endoscopic surgery versus intensity-modulated radiotherapy (IMRT) in patients with resectable locally recurrent NPC. ⋯ Sun Yat-sen University Clinical Research 5010 Program.
-
The lancet oncology · Mar 2021
Meta AnalysisIntermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.
The international Intermediate Clinical Endpoints in Cancer of the Prostate working group has established metastasis-free survival as a surrogate for overall survival in localised prostate cancer based on the findings of 19 predominantly radiotherapy-based trials. We sought to comprehensively assess aggregate trial-level performance of commonly reported intermediate clinical endpoints across all randomised trials in localised prostate cancer. ⋯ Prostate Cancer Foundation and National Institutes of Health.
-
The lancet oncology · Mar 2021
Randomized Controlled Trial Multicenter Study Comparative Study4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial.
The optimal radiotherapy dose for indolent non-Hodgkin lymphoma is uncertain. We aimed to compare 24 Gy in 12 fractions (representing the standard of care) with 4 Gy in two fractions (low-dose radiation). ⋯ Cancer Research UK.